Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
THDBH110
- Development stage
- Phase 1
- Lead developer
- Dongbao Zixing
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
THDBH110 is an investigational small molecule agonist of the G protein-coupled receptor 40 (GPR40), also known as free fatty acid receptor 1 (FFAR1), being developed by Dongbao Zixing (Hangzhou) Biopharmaceutical, a subsidiary of Tonghua Dongbao Pharmaceutical. Designed for the treatment of type 2 diabetes mellitus, THDBH110 targets receptors primarily expressed in pancreatic beta cells. Its mechanism of action involves enhancing glucose-stimulated insulin secretion (GSIS) in a glucose-dependent manner, which potentially offers improved glycemic control with a reduced risk of hypoglycemia compared to traditional insulin secretagogues like sulfonylureas. The drug is currently in early-stage clinical development in China.
02
Targets
GLP1R (GLP-1R)FFAR1 (Free fatty acid receptor 1)
Beyond the preview
Go deeper on THDBH110.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on THDBH110.